Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
78°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Entrada Therapeutics Inc
(NQ:
TRDA
)
16.52
+0.41 (+2.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Entrada Therapeutics Inc
< Previous
1
2
3
4
Next >
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 13, 2024
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Entrada Therapeutics Reports Second Quarter 2024 Financial Results
August 13, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces $100 Million Registered Direct Offering
June 24, 2024
– The offering was led by a U.S.-based healthcare focused investor, two global mutual funds and Janus Henderson Investors, a global asset management firm –
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy
June 24, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Recap: Entrada Therapeutics Q4 Earnings
March 13, 2024
Via
Benzinga
Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
May 16, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
TRDA Stock Earnings: Entrada Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 07, 2024
TRDA stock results show that Entrada Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Entrada Therapeutics Reports First Quarter 2024 Financial Results
May 07, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
April 11, 2024
Via
Benzinga
Insiders Buying America's Car-Mart And 2 Other Stocks
April 11, 2024
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.
Via
Benzinga
Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying
March 22, 2024
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.
Via
Benzinga
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 13, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
February 07, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Promotes Nathan J. Dowden to President
January 03, 2024
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know
November 27, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
November 23, 2023
Via
Benzinga
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?
November 22, 2023
Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
November 22, 2023
Via
Benzinga
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
November 22, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
October 12, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
September 21, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
September 07, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
August 29, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
August 10, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
August 08, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
August 01, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
June 26, 2023
Via
Benzinga
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Entrada Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.